COMMUNIQUÉS West-GlobeNewswire

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
03/09/2025
New longer-term post hoc analysis results of responders (n=6) 1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain [...]
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
03/09/2025
GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
03/09/2025
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral [...]
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
03/09/2025
Live moderated webcast on Thursday, September 4 th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company [...]
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
03/09/2025
PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior [...]
Journey Medical Corporation to Participate in September 2025 Investor Conferences
03/09/2025
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing [...]
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
03/09/2025
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
03/09/2025
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated [...]
Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models
03/09/2025
Renovamen Advisors ® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models Guiding biotech teams from scientific breakthroughs to commercial inflection with investor- [...]
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
03/09/2025
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc. , [...]
Fangzhou Secures 2nd National Science Foundation Project Approval, Deepens AI-Driven Healthcare Research
03/09/2025
SHANGHAI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its technology team will collaborate on a National [...]
WeightWatchers Advances International Growth With Strategic Leadership Appointment
03/09/2025
Alejandro Bethlen to Lead WeightWatchers’ Next Phase of International Growth and Innovation, Building on More Than 50 Years in Global Markets NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: [...]
Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme
03/09/2025
Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappel Forte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les [...]
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
03/09/2025
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring [...]
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
03/09/2025
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and [...]
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
03/09/2025
Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27 th Annual Global [...]
Best Kratom Brand Products For Energy and Pain: Happy Go Leafy Introduces New Kratom Collection in 2025
03/09/2025
Discover premium, lab-tested Kratom products designed to boost energy, relieve pain, and support overall wellness with Happy Go Leafy’s 2025 collection. Glendale, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Happy Go Leafy [...]
Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment
03/09/2025
Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciences Allegro prepares to advance lead product hydrocelin into [...]
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
03/09/2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]

Pages